ClinicalTrials.gg
CompletedNCT03991754PAF-TAVIUpdated Sep 30, 2026

Prevention of New Onset AF After TAVI (PAF-TAVI Trial)

A Phase 3 interventional study of Amiodarone and Placebo in Atrial Fibrillation New Onset, sponsored by Ana Belen Rivas Paterna. Completed at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Ana Belen Rivas Paterna · Phase 3, Interventional, and Prevention

How we know

Updated Sep 30, 2026Now CompletedFirst site in Spain+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing amiodarone in Atrial Fibrillation — 12 open to participants now, 12 under way, 3 of them phase 3. Amiodarone · Atrial Fibrillation.

Enrollment
25th of 46
121 · median 124
Started
2020
the only one that year
Phase 3
12 of 46
3 open now
Registered
28th of 46
by date
Lead sponsor
1 of 46
Ana Belen Rivas Paterna

Among the 46 studies testing amiodarone in Atrial Fibrillation, this one is the 25th largest by enrollment, is the only one that started in 2020, is one of 12 in phase 3, and was the 28th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

12 of the 46 studies testing amiodarone in Atrial Fibrillation are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About amiodarone

Amiodarone: first FDA approval 1985 (CORDARONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing amiodarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

New onset atrial fibrillation (NOAF) is a relatively frequent complication after transcatheter aortic valve implantation (TAVI). This complication has been related with worse short and long-term outcomes, including higher stroke, mortality, readmission and bleeding rates. The aim of this study is to evaluate the effectiveness of amiodarone in the prevention of the NOAF after TAVI.

The study is a multicenter, randomized double-blinded trial including 120 patients without prior AF that will undergo TAVI in a scheduled basis. Patients will be randomized to be treated with amiodarone orally from 6 days before to 6 days after the TAVI procedure versus placebo.

All the patients will be monitored with a 60-day holter to evaluate NOAF incidence. The main objective is NOAF incidence after TAVI at 30-day. Secondary endpoints are the incidence of NOAF, stroke, bleeding and all-cause and cardiovascular mortality in both groups at 60-day. Results of this study can contribute to optimize TAVI results in a short and long term, potentially improving the survival and quality of life in this group of frail patients with comorbidities, which makes them vulnerable to NOAF, stroke, bleeding, heart failure and readmission.

03

Conditions studied

  • Atrial Fibrillation New Onset

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women over 18 years old. Women of childbearing age must commit to the use of methods of assured efficacy.
  • Patients that will undergo TAVI due to aortic stenosis.
  • Sinus rhythm showed by an during 72 hours previous to the inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation. Women of childbearing age who do not have a negative pregnancy test.
  • Paroxysmal persistent or persistent AF (documented record in or ECG holter)
  • Congestive heart failure with functional class IV despite optimal medical treatment.
  • Sustained hypotension (TAS \< 80mmHg)
  • Severe mitral stenosis or regurgitation
  • Treatment with antiarrhythmic drugs (amiodarone included) 3 months before the procedure, treatment with beta-blockers or dihydropyrimidine calcium channel blockers are not considered an exclusion criteria.
  • Sinus bradycardia (\< 50 lpm), PR interval >240 mseg or second or third degree AV block.
  • longer than 480 msec in an EKG performed in 72 hours before the inclusion, without a permanent pacemaker.
  • Clinical hypo- or hyperthyroidism, clinical or subclinical thyroid disease, or multinodular goiter.
  • Allergy or adverse reaction known or suspected to the amiodarone.
  • Denial of the patient or inability to give .
  • to iodo
  • Concomitant drugs that, in association with amiodarone, can induce torsades de pointes
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Amiodarone

    Oral Amiodarone 600mg / day, divided into 3 doses (200mg every 8 hours) for 6 days before the procedure and then 400mg / day, divided into 2 doses (200mg every 12 hours) during the 6 days following the implantation of TAVI.

    Drug: Amiodarone

  • Placebo comparator
    Control

    Patients assigned to the control group will receive placebo tablets identical to those of amiodarone. The administration of these tablets will follow the same scheme as in the amiodarone group. Therefore, they will receive placebo tablets orally, 1 tablet every 8 hours 6 days before the procedure and then 1 tablet every 12 hours during the 6 days following the implantation of TAVI

    Drug: Placebo

Interventions

  • Oral Amiodarone 600mg / day for 6 days before the procedure and then 400mg / day following the implantation of TAVI.

  • DrugPlacebo

    1 tablet of placebo/8 hours 6 days before the procedure and then 1 tablet/12 hours during the 6 days following the implantation of TAVI

06

What researchers measure

Primary outcomes

  1. Incidence of new onset atrial fibrillation

    Compare the incidence of new onset atrial fibrillation (NOAF) on patients that receive oral amiodarone versus placebo. NOAF is defined as an irregular rhythm without P wave and irregular ventricular response during at least 30 seconds, detected in the electrocardiographic monitoring during the post-procedural period or in the 60 days ECG Holter in a patient without previous history of atrial fibrillation. NOAF incidence within 30-day after the TAVI procedure is the primary end-point.

    Time frame: 30 days after transcatheter aortic valve implantation (TAVI)

Secondary outcomes

  1. Incidence of new onset atrial fibrillation

    Compare the incidence of new onset atrial fibrillation (NOAF) on patients that receive oral amiodarone versus placebo. NOAF is defined as an irregular rhythm without P wave and irregular ventricular response during at least 30 seconds, detected in the electrocardiographic monitoring during the post-procedural period or in the 60 days ECG Holter in a patient without previous history of atrial fibrillation. NOAF incidence within 30-day after the TAVI procedure is the primary end-point.

    Time frame: 60 days after transcatheter aortic valve implantation (TAVI)

  2. Effect of the amiodarone

    Analyze the effect of the amiodarone in the moment of appearance and the burden of AF after TAVI. AF burden, defined as the relative length of the AF registers in relation to the time in sinus rhythm.

    Time frame: 1-year follow-up

  3. Mortality and cardiovascular (CV) mortality.

    Compare all-cause mortality and CV mortality between groups.

    Time frame: 1-year follow-up

  4. Number of patients with major adverse cardiac event (MACE)

    MACE: Stroke, bleeding (major or life-threatening), and all-cause and cardiovascular mortality rate.

    Time frame: at 30 days after NOAF

  5. Number of patients with MACE

    MACE: Stroke, bleeding (major or life-threatening), and all-cause and cardiovascular mortality rate.

    Time frame: at 60 days after NOAF

  6. Number of patients with MACE

    MACE: Stroke, bleeding (major or life-threatening), and all-cause and cardiovascular mortality rate.

    Time frame: at 6 months after NOAF

  7. Number of patients with MACE

    MACE: Stroke, bleeding (major or life-threatening), and all-cause and cardiovascular mortality rate.

    Time frame: 1-year follow-up

  8. Number of adverse events related to amiodarone

    The safety evaluation will be realized by a meticulous vigilance of the adverse effects appeared in the study population.

    Time frame: at 30 days after NOAF

  9. Number of adverse events related to amiodarone

    The safety evaluation will be realized by a meticulous vigilance of the adverse effects appeared in the study population.

    Time frame: at 60 days after NOAF

  10. Number of adverse events related to amiodarone

    The safety evaluation will be realized by a meticulous vigilance of the adverse effects appeared in the study population.

    Time frame: at 6 months after NOAF

  11. Number of adverse events related to amiodarone

    The safety evaluation will be realized by a meticulous vigilance of the adverse effects appeared in the study population.

    Time frame: 1-year follow-up

  12. Incidence of permanent pacemaker implantation in the both groups.

    Need of permanent pacemaker implantation in the both groups.

    Time frame: at 30 days after NOAF

  13. Incidence of permanent pacemaker implantation in the both groups.

    Need of permanent pacemaker implantation in the both groups.

    Time frame: at 60 days after NOAF

  14. Incidence of permanent pacemaker implantation in the both groups.

    Need of permanent pacemaker implantation in the both groups.

    Time frame: at 6 months after NOAF

  15. Incidence of permanent pacemaker implantation in the both groups.

    Need of permanent pacemaker implantation in the both groups.

    Time frame: 1-year follow-up

  16. Quality of life: EuroQoL 5D

    Eq-5D: EuroQoL 5 Dimensions. Score between 0 and 1. The best score 1.

    Time frame: at 30 days after NOA

  17. Quality of life: Kansas City test

    Score between 0 and 100. The best score 100.

    Time frame: at 30 days after NOA

  18. Quality of life: EuroQoL 5D

    Eq-5D: EuroQoL 5 Dimensions. Score between 0 and 1. The best score 1.

    Time frame: at 60 days after NOAF

  19. Quality of life: Kansas City test

    Score between 0 and 100. The best score 100.

    Time frame: at 60 days after NOAF

  20. Quality of life: EuroQoL 5D

    Eq-5D: EuroQoL 5 Dimensions. Score between 0 and 1. The best score 1.

    Time frame: at 6 months after NOAF

  21. Quality of life: Kansas City test

    Score between 0 and 100. The best score 100.

    Time frame: at 6 months after NOAF

  22. Quality of life: EuroQoL 5D

    Eq-5D: EuroQoL 5 Dimensions. Score between 0 and 1. The best score 1.

    Time frame: 1-year follow-up

  23. Quality of life: Kansas City test

    Score between 0 and 100. The best score 100.

    Time frame: 1-year follow-up

  24. Readmissions due to CV causes

    Compare the number of readmissions due to CV causes

    Time frame: 1-year follow-up

  25. Functional change: New York Heart Association.

    Evaluate the functional change according to the NYHA scale. Score between 0 and 4. The best score 1.

    Time frame: at 30 days after NOA

  26. Functional change: New York Heart Association.

    Evaluate the functional change according to the NYHA scale. Score between 0 and 4. The best score 1.

    Time frame: at 60 days after NOAF

  27. Functional change: New York Heart Association.

    Evaluate the functional change according to the NYHA scale. Score between 0 and 4. The best score 1.

    Time frame: at 6 months after NOAF

  28. Functional change: New York Heart Association.

    Evaluate the functional change according to the NYHA scale. Score between 0 and 4. The best score 1.

    Time frame: 1-year follow-up

  29. Capacity for the exercise

    Assess the change in capacity for the exercise, evaluated by the 6-minute walk test between groups

    Time frame: at 30 days after NOA

  30. Capacity for the exercise

    Assess the change in capacity for the exercise, evaluated by the 6-minute walk test between groups

    Time frame: at 60 days after NOAF

  31. Capacity for the exercise

    Assess the change in capacity for the exercise, evaluated by the 6-minute walk test between groups

    Time frame: at 6 months after NOAF

  32. Capacity for the exercise

    Assess the change in capacity for the exercise, evaluated by the 6-minute walk test between groups

    Time frame: 1-year follow-up

  33. Incidence of Acute renal failure

    Compare the number of events due to acute renal failure between groups

    Time frame: baseline

  34. Incidence of Acute renal failure

    Compare the number of events due to acute renal failure between groups

    Time frame: 30 days after NOA

07

Study locations

6 sites
  • Complejo Asistencial Universitario de Salamanca
    Salamanca, Salamanca, Spain
  • Hospital Clínic Barcelona
    Barcelona, Spain
  • Hospital Clínico San Carlos
    Madrid, Spain
  • Hospital de La Princesa
    Madrid, Spain
  • Hospital Marqués de Valdecilla
    Santander, Spain
  • Hospital Clínico de Valladolid
    Valladolid, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Oct 2022, 32 months.

Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's 32 months is below that.

Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Jun 2019 → Jan 2020, primary completion Dec 2021 → Oct 2022 and completion Jun 2022 → Jun 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2019
First posted
Jun 19, 2019
StartActual
Jan 30, 2020was Jun 2019
Primary completionActual
Oct 9, 2022was Dec 2021
CompletionActual
Jun 13, 2023was Jun 2022
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Sep 30, 2026
Sites
6 sites added — first site in Spain
Show 6 added (6 Spain)
  • Complejo Asistencial Universitario de Salamanca · Salamanca, Spain
  • Hospital Clínic Barcelona · Barcelona, Spain
  • Hospital Clínico San Carlos · Madrid, Spain
  • Hospital de La Princesa · Madrid, Spain
  • Hospital Marqués de Valdecilla · Santander, Spain
  • Hospital Clínico de Valladolid · Valladolid, Spain
Sep 30, 2026
Start date
Jun 30, 2019→Jan 30, 2020 (actual)
Sep 30, 2026
Primary completion
Dec 31, 2021→Oct 9, 2022 (actual)
Sep 30, 2026
Study completion
Jun 30, 2022→Jun 13, 2023 (actual)
Sep 30, 2026
Enrollment
120 (estimated)→121 (actual)
Sep 30, 2026
Interventions
Added Drug: Amiodarone·Drug: Placebo; removed Procedure: transcatheter aortic valve implantation
Sep 30, 2026
Secondary outcomes
5 edited, 4 description edited
What changed in the outcomes
  • EditedMortality and cardiovascular (CV) mortality.Time frame: 1-year follow-up
  • EditedNumber of parientspatients with major adverse cardiac event (MACE)Time frame: at 30 days after NOAF
  • EditedNumber of parientspatients with MACETime frame: at 60 days after NOAF
  • EditedNumber of parientspatients with MACETime frame: at 6 months after NOAF
  • EditedNumber of parientspatients with MACETime frame: 1-year follow-up
  • DescriptionCapacity for the exercise: how it is measured was reworded
  • DescriptionCapacity for the exercise#2: how it is measured was reworded
  • DescriptionCapacity for the exercise#3: how it is measured was reworded
  • DescriptionCapacity for the exercise#4: how it is measured was reworded
Sep 30, 2026
Sponsor
Luis Nombela Franco→Ana Belen Rivas Paterna
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Status unknown→Completed
    6 sites added — first site in Spain
    Show 6 added (6 Spain)
    • Complejo Asistencial Universitario de Salamanca · Salamanca, Spain
    • Hospital Clínic Barcelona · Barcelona, Spain
    • Hospital Clínico San Carlos · Madrid, Spain
    • Hospital de La Princesa · Madrid, Spain
    • Hospital Marqués de Valdecilla · Santander, Spain
    • Hospital Clínico de Valladolid · Valladolid, Spain
    Start date Jun 30, 2019→Jan 30, 2020 (now actual)
    Primary completion Dec 31, 2021→Oct 9, 2022 (now actual)
    Study completion Jun 30, 2022→Jun 13, 2023 (now actual)
    Enrollment 120 (estimated)→121 (actual)
    Secondary outcomes 5 edited, 4 description edited
    What changed in the outcomes
    • EditedMortality and cardiovascular (CV) mortality.Time frame: 1-year follow-up
    • EditedNumber of parientspatients with major adverse cardiac event (MACE)Time frame: at 30 days after NOAF
    • EditedNumber of parientspatients with MACETime frame: at 60 days after NOAF
    • EditedNumber of parientspatients with MACETime frame: at 6 months after NOAF
    • EditedNumber of parientspatients with MACETime frame: 1-year follow-up
    • DescriptionCapacity for the exercise: how it is measured was reworded
    • DescriptionCapacity for the exercise#2: how it is measured was reworded
    • DescriptionCapacity for the exercise#3: how it is measured was reworded
    • DescriptionCapacity for the exercise#4: how it is measured was reworded
    Interventions Added Drug: Amiodarone·Drug: Placebo; removed Procedure: transcatheter aortic valve implantation
    Sponsor Luis Nombela Franco→Ana Belen Rivas Paterna
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03991754
Lead sponsor
Ana Belen Rivas Paterna
Responsible party
Ana Belen Rivas Paterna (Principal Investigator, Hospital San Carlos, Madrid) — Sponsor-investigator
First posted
Jun 19, 2019
Start date
Jan 30, 2020
Primary completion
Oct 9, 2022
Completion
Jun 13, 2023
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amiodarone

Start the discussion